Drugs Containing Excipient (Inactive Ingredient) COCO-BETAINE

« Back to Dashboard

Branded drugs containing COCO-BETAINE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	CLOBEX	clobetasol propionate	0299-3847	COCO-BETAINE

Generic drugs containing COCO-BETAINE excipient

Company	Ingredient	NDC	Excipient
Galderma Laboratories LP	clobetasol propionate	0299-3847	COCO-BETAINE
Actavis Pharma Inc	clobetasol propionate	0472-0403	COCO-BETAINE
NORTHSTAR RX LLC	clobetasol propionate	16714-030	COCO-BETAINE
Medimetriks Pharmaceuticals	clobetasol propionate	43538-950	COCO-BETAINE

COCO-BETAINE Market Dynamics and Financial Trajectory in Pharmaceutical Excipients

Last updated: October 10, 2026

Coco-betaine is a specialty amphoteric surfactant with a limited, nontransparent pharmaceutical market. Its commercial base is personal care, household cleaning, and industrial formulations rather than finished medicines. Pharmaceutical demand is constrained by regulatory qualification, impurity control, batch consistency, and competition from established excipients such as polysorbates, poloxamers, sodium lauryl sulfate, and other betaine derivatives.

No public financial statements separately report coco-betaine revenue. Its financial trajectory must therefore be assessed through end-market exposure, raw-material costs, regulatory barriers, supplier concentration, and broader amphoteric-surfactant demand.

What is coco-betaine and how is it used?

Coco-betaine is a zwitterionic surfactant derived from coconut fatty acids and betaine chemistry. It is generally used for mild cleansing, foam generation, wetting, antistatic performance, and compatibility with anionic and nonionic surfactants.

The material is often confused with cocamidopropyl betaine. The two ingredients are related but chemically distinct:

Attribute	Coco-betaine	Cocamidopropyl betaine
Common identity	Alkyl betaine derived from coconut fatty acids	Amidoamine-derived betaine
Typical CAS reference	66455-29-6 is commonly associated with coco-betaine	61789-40-0 is commonly associated with cocamidopropyl betaine
Primary commercial market	Personal care and cleansing products	Personal care, cleansing, and specialty formulations
Pharmaceutical role	Potential excipient or formulation aid	More widely recognized in cleansing and topical applications
Main performance	Mild surfactancy, foam, compatibility	Foam stabilization, viscosity response, mild cleansing
Principal regulatory issue	Composition variability and residual impurities	Amidoamine and DMAPA-related impurity control

Commercial coco-betaine is usually not a single molecular species. It is a mixture of alkyl betaines and associated manufacturing components. Fatty-chain distribution, active-matter concentration, sodium chloride, unreacted amines, residual solvents, color, odor, and microbiological quality can vary by supplier and grade.

That composition profile matters in pharmaceutical development. A material accepted for shampoo or liquid soap may not be suitable for an oral, ophthalmic, inhaled, injectable, or sensitive topical drug product.

What pharmaceutical applications use coco-betaine?

Pharmaceutical use is most plausible in topical, dermatological, cleansing, and occasionally oral-care products. Publicly available information does not establish coco-betaine as a broadly adopted excipient in high-value prescription medicines.

Potential applications include:

• Medicated shampoos and scalp treatments
• Topical cleansers and wash-off dermatological products
• Liquid formulations requiring mild surfactancy
• Oral-care or mucosal cleansing products
• Veterinary topical products
• Drug-device cleaning or pre-treatment formulations
• Certain consumer health products regulated as drugs or quasi-drug products outside the United States

Coco-betaine is less attractive for systemic oral dosage forms because surfactants can create tolerability, taste, permeability, and gastrointestinal compatibility issues. It is generally unsuitable for parenteral products unless a highly controlled, pharmaceutical-grade material has been specifically qualified.

For topical products, the main technical question is usually whether coco-betaine adds meaningful performance relative to better-characterized alternatives. Developers must evaluate irritation, sensitization, residual amines, microbial quality, preservative compatibility, viscosity, foam, pH, and interaction with the active pharmaceutical ingredient.

What is the FDA regulatory status of coco-betaine?

Coco-betaine is not independently approved by the FDA as a drug ingredient. Excipients generally receive regulatory acceptance through their use in a specific drug product reviewed under an application, rather than through a standalone approval pathway.

The relevant regulatory sources are:

1. FDA-approved drug labeling and product applications
2. The FDA Inactive Ingredient Database, or IID
3. United States Pharmacopeia-National Formulary standards, where applicable
4. Drug Master Files and supplier quality packages
5. Safety and toxicology data supporting the intended route and concentration

The FDA IID should be checked by exact ingredient name, synonym, dosage form, route, and maximum potency. A listing for a related ingredient, such as cocamidopropyl betaine, does not establish that coco-betaine is interchangeable.

A sponsor using coco-betaine must establish that:

• The exact chemical identity is defined
• The proposed grade is consistent from batch to batch
• Impurities are controlled
• The level is justified for the route of administration
• The material does not compromise product stability
• The formulation is adequately tested for irritation and sensitization
• The supplier has suitable quality and change-control systems

A non-IID or limited-IID ingredient can still be used, but the regulatory burden is higher. The sponsor may need additional safety data, a justification for the selected concentration, and detailed manufacturing information.

What is the Orange Book status of coco-betaine?

Coco-betaine has no independent Orange Book status because the Orange Book lists approved drug products and associated patent and exclusivity information, not ordinary excipients as standalone commercial products.

There is no conventional Orange Book exclusivity period for coco-betaine. It does not receive:

• New chemical entity exclusivity
• New formulation exclusivity
• Orphan-drug exclusivity
• Pediatric exclusivity
• Standalone patent-term protection as an excipient

A drug product containing coco-betaine could have patents covering its formulation, method of treatment, dosage form, or manufacturing process. Those rights would attach to the finished drug product, not automatically to coco-betaine as a commodity ingredient.

What patents protect coco-betaine?

The direct patent position for coco-betaine is weaker than for proprietary delivery systems or novel excipients. The underlying chemistry is established, and commercially available coco-betaine is generally supplied as a commodity or specialty surfactant mixture.

Relevant patent categories include:

Patent category	Likely protection scope	Commercial impact
Composition patents	Defined betaine structures or mixtures	Usually limited where chemistry is established
Manufacturing patents	Reaction conditions, purification, feedstock treatment	Can protect cost, purity, or performance advantages
Formulation patents	Use in a specific drug or topical composition	More relevant to finished products
Method-of-use patents	Treatment or cleansing use with a drug	Product-specific rather than ingredient-wide
Process-control patents	Low-impurity or narrow-chain-distribution material	Potential supplier differentiation
Delivery-system patents	Surfactant combinations, micelles, emulsions, or nanoparticles	May create meaningful barriers in specialized products

No widely recognized, ingredient-wide patent estate is publicly associated with standard commercial coco-betaine that would prevent multiple manufacturers from supplying the material. The primary barriers are more likely to be know-how, quality documentation, customer qualification, and manufacturing economics.

Patent risk is higher when a supplier sells a proprietary low-impurity grade or a coco-betaine-containing delivery system. In those cases, infringement analysis must focus on claim language, not the ingredient name alone.

How strong is the pharmaceutical patent estate for coco-betaine?

The pharmaceutical patent estate is weak at the ingredient level and potentially stronger at the formulation level.

A typical pharmaceutical formulation patent may claim:

• A specified active ingredient
• Coco-betaine within a concentration range
• A defined pH range
• A viscosity or foam profile
• A preservative system
• A topical delivery vehicle
• A combination with polymers, lipids, or penetration enhancers

Such claims may be difficult to enforce against a competing product if the competitor uses a chemically different surfactant or omits coco-betaine. They may also be vulnerable to written-description, enablement, obviousness, or claim-construction challenges where the ingredient is used for a conventional surfactant function.

There is no normal Paragraph IV pathway for coco-betaine itself. Paragraph IV litigation applies to an abbreviated new drug application challenging listed patents for an approved reference drug. A generic drug containing coco-betaine could file a Paragraph IV certification against patents covering the finished product, but the challenge would concern the drug product rather than the excipient in isolation.

When does coco-betaine lose exclusivity?

Coco-betaine does not have a defined patent or regulatory exclusivity expiration date as a standalone excipient.

The relevant commercial “loss of exclusivity” event occurs at the finished-product level. A sponsor could lose practical protection when:

• A formulation patent expires
• A method-of-use patent expires
• A competing product demonstrates equivalent performance
• An alternative supplier qualifies a comparable grade
• A regulatory filing discloses enough formulation information to support replication
• A drug product becomes vulnerable to generic substitution

For a generic applicant, the principal opportunity is usually not to copy a proprietary coco-betaine grade. It is to design around the finished-product claims, qualify a different surfactant, or use coco-betaine within a noninfringing formulation.

What are the main market dynamics for pharmaceutical coco-betaine?

The market is shaped by five factors.

Personal-care demand sets the manufacturing base

Most coco-betaine volume is linked to shampoos, body washes, liquid soaps, facial cleansers, and related products. Pharmaceutical demand is too limited to determine global production economics. Personal-care growth can improve supply availability and manufacturing scale, while weak consumer demand can reduce plant utilization and increase unit costs for specialty grades.

Pharmaceutical qualification creates a price premium

Pharmaceutical customers pay for documentation, traceability, controlled impurities, validated testing, and change notification. The premium is not created by the base surfactant alone. It is created by the supplier’s quality system and the customer’s switching cost.

Once a drug manufacturer qualifies a grade, replacing it can require comparative formulation work, stability testing, toxicology review, and regulatory filing updates. That creates retention value even when the underlying chemical is not protected by patents.

Raw-material exposure affects margins

Coco-betaine economics are linked to:

• Coconut-derived fatty acids
• Dimethylaminopropylamine or related amine inputs
• Betaine chemistry
• Energy and processing costs
• Packaging
• Freight
• Preservatives and stabilizers
• Regional environmental and labor requirements

Feedstock volatility can move gross margins quickly because surfactant contracts often contain delayed or incomplete pass-through mechanisms. Suppliers with integrated fatty-acid sourcing or regional production may have a margin advantage.

Regulatory scrutiny favors better-controlled suppliers

Customers increasingly require detailed impurity profiles, allergen information, trace metals, residual solvents, microbial limits, and sustainability documentation. Suppliers unable to maintain consistent specifications may lose pharmaceutical and multinational personal-care accounts.

Substitution limits pricing power

Coco-betaine competes with cocamidopropyl betaine, sodium lauryl sulfate, sodium laureth sulfate, alkyl polyglucosides, amphoacetates, amphopropionates, poloxamers, polysorbates, and specialty nonionic surfactants. Substitution is not always one-for-one because each material changes viscosity, foam, irritation, preservative demand, and active compatibility. Even so, the presence of alternatives limits long-term pricing power.

What is the financial trajectory for coco-betaine?

The financial trajectory is likely to be stable-to-moderate growth rather than pharmaceutical-style expansion. Public companies generally aggregate coco-betaine into broader personal-care ingredients, surfactants, or specialty chemicals reporting. No reliable standalone revenue, EBITDA, or market-capitalization series exists for coco-betaine.

A practical financial model should separate three markets:

Market segment	Growth profile	Margin profile	Strategic value
Commodity personal care	Volume-driven	Low to moderate	Manufacturing scale
Premium personal care	Specification and branding-driven	Moderate	Customer retention
Pharmaceutical-grade supply	Qualification-driven	Moderate to high	Documentation and switching costs

The pharmaceutical segment can generate higher margins per kilogram but remains small in volume. Its value comes from repeat orders, qualification barriers, and long customer relationships. It is unlikely to materially change the financial performance of a diversified surfactant manufacturer unless the supplier owns a differentiated grade or a formulation platform.

The strongest financial scenario is a supplier that combines:

• Low-cost raw-material access
• Regional manufacturing
• Pharmaceutical-quality documentation
• Low impurity levels
• Strong change-control procedures
• Custom formulation support
• Supply contracts with multinational customers

The weaker scenario involves an undifferentiated supplier competing on price while relying on volatile imported feedstocks and lacking a documented pharmaceutical-grade system.

Which companies compete in the coco-betaine supply chain?

Competition is fragmented across specialty surfactant producers, oleochemical companies, and contract manufacturers. Potential suppliers vary by region and product grade. Major chemical groups with amphoteric-surfactant or personal-care ingredient portfolios may compete with regional manufacturers and private-label producers.

The relevant competitive variables are:

• Active-matter concentration
• Chain-length distribution
• Color and odor
• Residual amine levels
• Microbial control
• Packaging format
• Regional inventory
• GMP or pharmaceutical-quality support
• Regulatory documentation
• Customer-specific customization

A company should not be treated as a pharmaceutical-grade supplier solely because it sells a cosmetic-grade coco-betaine product. Supplier qualification requires review of the exact grade, manufacturing site, specifications, certificates of analysis, audit history, and change-control commitments.

What generic entry risks exist for drugs containing coco-betaine?

Generic entry risk depends on the finished drug, not on coco-betaine alone.

Risk is higher when:

• Coco-betaine is used for a conventional cleansing function
• The formulation is easy to reproduce
• The active ingredient has no meaningful device or delivery barrier
• The product has expired formulation patents
• The excipient is not essential to a distinctive performance profile
• Multiple suppliers offer comparable grades

Risk is lower when:

• The product relies on a narrow impurity profile
• The formulation uses a proprietary surfactant system
• The product is a complex topical or foam dosage form
• Clinical or comparative-performance data are difficult to replicate
• The patent claims cover a specific composition with measurable performance limits
• The supplier has an exclusive or deeply integrated relationship with the drug sponsor

Settlement agreements are generally relevant only to the finished pharmaceutical product. There is no standard industry-wide settlement structure governing generic access to coco-betaine itself.

How does coco-betaine compare with cocamidopropyl betaine?

Cocamidopropyl betaine has broader commercial recognition and a larger established user base in cleansing products. Coco-betaine may offer different mildness, foam, compatibility, and sensory properties, but substitution depends on the final formulation.

Factor	Coco-betaine	Cocamidopropyl betaine
Market maturity	Established but more specialized	Broadly established
Pharmaceutical visibility	Limited	Also limited, but more commonly encountered in topical and cleansing products
Impurity concern	Alkyl distribution and residual reaction components	DMAPA, amidoamine, and related impurities
Substitution	Often technically feasible after reformulation	Often technically feasible after reformulation
IP protection	Primarily formulation or process-based	Primarily formulation or process-based
Pricing power	Limited unless specialty grade	Limited unless specialty grade

Neither material has the regulatory position of a highly standardized compendial excipient such as polysorbate 80 or polyethylene glycol. Sponsors should avoid treating commercial familiarity as equivalent to regulatory acceptance.

What geographic factors affect coco-betaine supply?

Asia-Pacific is central to surfactant and personal-care ingredient production because of its manufacturing scale, feedstock access, and growing domestic demand. Europe and North America remain important for specialty grades, customer qualification, regulatory support, and high-value formulation work.

Geographic risk includes:

• Dependence on imported fatty-acid feedstocks
• Port and freight disruption
• Regional chemical regulations
• Environmental restrictions
• Currency movements
• Concentration of production in a small number of plants
• Customer qualification delays after site changes

Pharmaceutical customers often dual-source critical excipients, but dual sourcing is harder when the material has a narrow specification or the alternative supplier has not been audited.

Key Takeaways

• Coco-betaine is primarily a personal-care surfactant, not a major pharmaceutical excipient.
• Pharmaceutical demand is likely small in volume but can carry higher margins because of qualification and documentation requirements.
• No standalone coco-betaine exclusivity period, Orange Book listing, or conventional Paragraph IV pathway exists.
• Ingredient-level patent protection is limited; formulation, manufacturing, and impurity-control patents are more relevant.
• The main commercial risks are substitution, raw-material volatility, inconsistent composition, and limited pharmaceutical adoption.
• The strongest suppliers will combine low-cost production with pharmaceutical-quality documentation and reliable change control.
• Financial data must be analyzed through broader surfactant and specialty-ingredient segments because public companies do not separately disclose coco-betaine revenue.

FAQs

Is coco-betaine an FDA-approved pharmaceutical excipient?

No standalone FDA approval applies to coco-betaine. Its acceptability depends on the specific drug product, route, concentration, quality data, and regulatory filing.

Is coco-betaine listed in the Orange Book?

No. The Orange Book covers approved drug products and related patent and exclusivity information, not coco-betaine as an independent excipient.

Does coco-betaine have a patent expiration date?

Not as a standard commercial ingredient. Relevant expiration dates would belong to patents covering a specific formulation, manufacturing process, impurity profile, or delivery system.

Is coco-betaine the same as cocamidopropyl betaine?

No. They are different betaine surfactants with different chemical structures, impurity profiles, and performance characteristics.

Can a generic drug replace coco-betaine with another surfactant?

Potentially, but the applicant must demonstrate that the substitute produces equivalent performance, stability, safety, and regulatory compliance for the finished drug product.

References

1. European Chemicals Agency. (n.d.). Coco-betaine: Substance information. ECHA.

2. European Chemicals Agency. (n.d.). Cocamidopropyl betaine: Substance information. ECHA.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

6. Cosmetic Ingredient Review. (2012). Safety assessment of alkyl betaines as used in cosmetics. Cosmetic Ingredient Review.

7. PubChem. (n.d.). Coco-betaine. National Center for Biotechnology Information.